US 12,110,321 B2
Single domain antibodies for complement regulation
Nick Stub Laursen, Aarhus C (DK); Dennis Vestergaard Pedersen, Aarhus C (DK); Gregers Rom Andersen, Brabrand (DK); Steffen Thiel, Risskov (DK); Alessandra Zarantonello, Aarhus C (DK); Rasmus Kjeldsen Jensen, Aarhus C (DK); and Henrik Pedersen, Aarhus C (DK)
Assigned to Aarhus Universitet, Aarhus C (DK)
Appl. No. 17/251,023
Filed by Aarhus Universitet, Aarhus C (DK)
PCT Filed Jun. 11, 2019, PCT No. PCT/EP2019/065206
§ 371(c)(1), (2) Date Dec. 10, 2020,
PCT Pub. No. WO2019/238674, PCT Pub. Date Dec. 19, 2019.
Claims priority of application No. 18176954 (EP), filed on Jun. 11, 2018.
Prior Publication US 2021/0253682 A1, Aug. 19, 2021
Int. Cl. C07K 16/00 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 35/00 (2018.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
 
1. A single domain antibody capable of specifically binding to an epitope of a human and/or mouse C1q complement factor, wherein the single domain antibody comprises a complementarity determining region-1 (CDR1), a complementarity determining region-2 (CDR2), and a complementarity determining region-3 (CDR3); wherein:
(a) the CDR1 comprises the amino acid sequence of SEQ ID NO: 10, the CDR2 comprises the amino acid sequence of SEQ ID NO: 11, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 12;
(b) the CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the CDR2 comprises the amino acid sequence of SEQ ID NO: 15, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 16;
(c) the CDR1 comprises the amino acid sequence of SEQ ID NO: 18, the CDR2 comprises the amino acid sequence of SEQ ID NO: 19, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 20;
(d) the CDR1 comprises the amino acid sequence of SEQ ID NO: 22, the CDR2 comprises the amino acid sequence of SEQ ID NO: 23, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 24;
(e) the CDR1 comprises the amino acid sequence of SEQ ID NO: 26, the CDR2 comprises the amino acid sequence of SEQ ID NO: 27, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 28;
(f) the CDR1 comprises the amino acid sequence of SEQ ID NO: 30, the CDR2 comprises the amino acid sequence of SEQ ID NO: 31, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 32;
(g) the CDR1 comprises the amino acid sequence of SEQ ID NO: 34, the CDR2 comprises the amino acid sequence of SEQ ID NO: 35, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 36; or
(h) the CDR1 comprises the amino acid sequence of SEQ ID NO: 38, the CDR2 comprises the amino acid sequence of SEQ ID NO: 39, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 40.